We introduce and develop a new network-based and binless methodology to perform frequency analyses and produce histograms. In contrast with traditional frequency analysis techniques that use fixed intervals to bin values, we place a range ±ζ around each individual value in a data set and count the number of values within that range, which allows us to compare every single value of a data set with one another. In essence, the methodology is identical to the construction of a network, where two values are connected if they lie within a given a range (±ζ). The value with the highest degree (i.e., most connections) is therefore assimilated to the mode of the distribution. To select an optimal range, we look at the stability of the proportion of nodes in the largest cluster. The methodology is validated by sampling 12 typical distributions, and it is applied to a number of real-world data sets with both spatial and temporal components. The methodology can be applied to any data set and provides a robust means to uncover meaningful patterns and trends. A free python script and a tutorial are also made available to facilitate the application of the method.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631440 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142108 | PLOS |
JCO Clin Cancer Inform
January 2025
Machine Learning Department, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL.
Purpose: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression events. We evaluated whether an auxiliary data set could improve prediction performance.
View Article and Find Full Text PDFPLoS One
January 2025
Social & Scientific Systems, Inc., a DLH Holdings Company / United States Agency for International Development Strategic Information Technical Support Activity, Kampala, Uganda.
Tuberculosis (TB) stigma remains a significant barrier to TB control efforts globally, especially in countries with a high TB burden. Studies about TB stigma done in Uganda so far have been limited in scope and focused on data collected health facilities. In this study we report TB related stigma at community level for the period 2021/2022.
View Article and Find Full Text PDFStat Med
February 2025
Department of Statistics and Data Science, National University of Singapore, Singapore, Singapore.
The additive hazard model, which focuses on risk differences rather than risk ratios, has been widely applied in practice. In this paper, we consider an additive hazard model with varying coefficients to analyze recurrent events data. The model allows for both varying and constant coefficients.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
RAND Health, RAND, Boston, Massachusetts.
Importance: Long-term nursing home stay or death (long-term NH stay or death), defined as new long-term residence in a nursing home or death following hospital discharge, is an important patient-centered outcome.
Objective: To examine whether the COVID-19 pandemic was associated with changes in long-term NH stay or death among older adults with sepsis, and whether these changes were greater in individuals from racial and ethnic minoritized groups.
Design, Setting, And Participants: This cross-sectional study used patient-level data from the Medicare Provider Analysis and Review File, the Master Beneficiary Summary File, and the Minimum Data Set.
Blood Adv
January 2025
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.
Some CLL patients who develop progressive disease (PD) during treatment with covalent Bruton tyrosine kinase inhibitors (cBTKi) acquire pathway resistance mutations in BTK or PLCG2. Here, we report gene mutation data from paired baseline and PD peripheral blood samples from 52 patients (zanubrutinib, n=24; ibrutinib, n=28) who, at an early median follow-up time of 25.7 months, progressed on zanubrutinib or ibrutinib treatment in the ALPINE trial (NCT03734016).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!